申请人:Daiichi Sankyo Company, Limited
公开号:EP2974730A1
公开(公告)日:2016-01-20
It is intended to provide a therapeutic agent and/or a preventive agent for a respiratory disease or a therapeutic agent and/or a preventive agent for a sodium channel associated disease. The present invention provides a pharmaceutical comprising a compound represented by the following formula (I) or a pharmacologically acceptable salt thereof as an active ingredient:
Ar1 and Ar2 : a heteroaryl group or an aryl group; R1, R2 and R3: a hydrogen atom, a halogen atom, a C1-C6 alkyl group, a halogenated C1-C6 alkyl group, a hydroxy C1-C6 alkyl group, a C1-C6 alkoxy C1-C6 alkyl group or a C3-C7 cycloalkyl group or a cyano group; R4 and R5: a hydrogen atom, a halogen atom, a C1-C6 alkyl group, a halogenated C1-C6 alkyl group, a hydroxyl group, a hydroxy C1-C6 alkyl group, a C1-C6 alkoxy C1-C6 alkyl group, a C3-C7 cycloalkyl group or a C1-C6 alkoxy group;
n: an integer of 1 to 3; and
the heteroaryl or aryl group optionally has one or two groups independently selected from a halogen atom, a C1-C6 alkyl group, a halogenated C1-C6 alkyl group, a hydroxyl group, a hydroxy C1-C6 alkyl group, a C1-C6 alkoxy C1-C6 alkyl group, a C3-C7 cycloalkyl group, a carboxyl group, a cyano group, an amino group, a C1-C3 alkylamino group and a di-C1-C3 alkylamino group, and when the heteroaryl or aryl group has two such groups, the two groups are the same as or different from each other.
本发明旨在提供一种呼吸系统疾病的治疗剂和/或预防剂,或一种
钠通道相关疾病的治疗剂和/或预防剂。本发明提供了一种包含下式(I)代表的化合物或其药理学上可接受的盐作为活性成分的药物:
Ar1和Ar2:杂芳基或芳基; R1、R2和R3:氢原子、卤素原子、C1-C6烷基、卤代C1-C6烷基、羟基C1-C6烷基、C1-C6烷氧基C1-C6烷基或C3-C7环烷基或
氰基; R4和R5:氢原子、卤素原子、C1-C6 烷基、卤代 C1-C6 烷基、羟基、羟基 C1-C6 烷基、C1-C6 烷氧基 C1-C6 烷基、C3-C7 环烷基或 C1-C6 烷氧基;
n:1 至 3 的整数;以及
杂芳基或芳基任选具有一个或两个独立选自卤素原子、C1-C6 烷基、卤代 C1-C6 烷基、羟基、羟基 C1-C6烷基、C1-C6 烷氧基 C1-C6烷基、C3-C7 环烷基、羧基、
氰基、
氨基、C1-C3 烷基
氨基和二-C1-C3 烷基
氨基的基团,当杂芳基或芳基具有两个此类基团时,这两个基团彼此相同或不同。